Latest news with #EmmanuelPapadakis
Globe and Mail
3 days ago
- Business
- Globe and Mail
Deutsche Bank Reaffirms Their Hold Rating on AstraZeneca (AZN)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with a price target of £110.00. The company's shares opened today at p10,720.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, AstraZeneca, and Novartis AG. According to TipRanks, Papadakis has an average return of 3.8% and a 52.91% success rate on recommended stocks. Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of p13,229.38. Based on AstraZeneca's latest earnings release for the quarter ending March 30, the company reported a quarterly revenue of p13.59 billion and a net profit of p2.92 billion. In comparison, last year the company earned a revenue of p12.68 billion and had a net profit of p2.18 billion Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AZN in relation to earlier this year.
Business Insider
6 days ago
- Business
- Business Insider
UBS Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) on May 31 and set a price target of DKK700.00. Confident Investing Starts Here: Walton covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Bayer, and Sanofi. According to TipRanks, Walton has an average return of -0.5% and a 52.08% success rate on recommended stocks. In addition to UBS, Novo Nordisk also received a Buy from Deutsche Bank 's Emmanuel Papadakis in a report issued on May 27. However, on May 16, Berenberg Bank maintained a Hold rating on Novo Nordisk (LSE: 0QIU). 0QIU market cap is currently DKK2013.8B and has a P/E ratio of 19.73. Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0QIU in relation to earlier this year.
